the glucose levels measured after an overnight fast may not be indicative of the metabolic target glucose levels of individuals with type 2 diabetes.
Several test protocols and mathematical modeling strategies have been developed to quantify key elements of dysfunction in type 2 diabetes. [10] [11] [12] The dynamic insulin sensitivity and secretion test (DISST) is a low intensity alternative to the insulin-modified intravenous glucose tolerance test (IM-IVGTT). 13 The DISST insulin sensitivity metric (SI) is well correlated to the euglycemic hyperinsulinemic clamp ISI (R = 0.82) and produced repeatable endogenous insulin secretion metrics in a nondiabetic cohort. [12] [13] [14] [15] However, the DISST model was developed to distinguish between healthy and prediabetes states and was not tested thoroughly in individuals with established diabetes.
Like most model-based assessments of SI, [16] [17] [18] [19] the typical DISST model approach uses the participant's first glucose measurement (G 0 ) as the glucose concentration that the model will theoretically reach at equilibrium (G TARGET , G TARGET = G( t )). The DISST model also typically assumes that G 0 = G TARGET . However, numerous studies have shown this assumption is not valid in established type 2 diabetes due to the extended fasting period needed to reach plasma glucose equilibrium. [6] [7] [8] [9] 20 In particular, Othman et al 20 showed that an identified G TARGET levels were significantly different to G 0 and that variability in the parameter yielded much improved model fits for individuals with type 2 diabetes. In contrast, the typical assumption led to large and consistently biased model residuals. This evidence suggests that the G TARGET . Participants were excluded if they had major physiological or psychological illness at the time of testing. Pregnant or lactating females were also excluded. Two participants discontinued the intervention, the first citing personal reasons, and the second left the study due to exacerbation of a renal stone. Twelve participants completed the study. Table 1 shows the height, age, and BMI of these 12 individuals. Full demographic details and results of the intervention study have been previously described by Krebs et al. 21 Ethical approval for this study was provided by the New Zealand Ministry of Health, Central Regional Ethics Committee.
Clinical Procedure
The clinical protocol in this study was similar to the protocol defined by Ward et al. 22 All procedures were started at the morning after an overnight fast. A 0.2 g/kg glucose bolus was administered at t = 1 minute and then an infusion of insulin that was intended to replicate the insulinemic response of a normoglycemic individual was administered. An insulin infusion was started at t = 2 minutes at a rate of 3.5 mU/kg/min and was reduced to 0.5 mU/kg/min at t = 7 minutes. Further reductions to 0.25 mU/kg/min, occurred at t = 17 minutes, and to 0.1 mU/kg/min at t = 50 minutes, respectively. The infusion of 0.1mU/kg/min was maintained for the remainder of the procedure. Venous blood samples were taken into ∞ 
Dynamic Insulin Sensitivity and Secretion Test (DISST) Model
This analysis used the DISST model of interstitial insulin kinetics and glucose dynamics:
where equation nomenclature is shown in Table 2 .
Modeling Approaches
Two models were fit to the measured glucose and insulin data. Both models used the DISST model from equations 1-3. However, the models differ in their interpretation of the target glucose level. The models are named:
SFA: Standard fasting assumption VGT: Variable glucose target
The SFA model conforms to the typical assumption that G TARGET = G 0 and defines SI and V G as model variables.
13,14
The VGT model captures the potential variability in G TARGET by calculating SI, V G and G TARGET in concert. Hence, the SFA has two model variables and the VGT has three model variables. The DISST model defines n C , n I and p G as a priori functions of anatomical data. [12] [13] [14] 23 The SFA and GFT model were both tested for identifiability using the methods of Baker et al, 24 showing the model remains structurally identifiable, which is further confirmed by the fact that the additional dynamic is observable and well captured by this identified parameter. Calculation of the model variables was undertaken using the Gauss Newton model optimization method. 25 T for the VGT. Numerical Jacobians were determined with Δx values of 0.001% of the initial conditions. Fifty iterations of Gauss Newton were used for each dataset. Glucose samples between t = 1 and t = 10 minutes were disregarded, as this period is heavily influenced by mixing kinetics that are not well captured by whole body models of glucose metabolism. 14, 26 G TARGET was limited to values greater than 3 mmol·L -1 to mitigate the occurrence of unphysiological values. 27 These constraints extend beyond reported physiologically realistic values and mitigate only un-plausible solutions.
Analysis
The distributions of SI, G 0 , and G TARGET values were compared across the SFA and VGT models using the signed rank sum (P rs ) and Kolmogorov-Smirnov (P ks ) tests. The signed rank sum test compares the specific participant matched SI results from the SFA and VGT models. The KolmogorovSmirnov test is sensitive to differences in both location and Insulin sensitivity Calculated shape of the empirical cumulative distribution functions of SI distributions from the two approaches. A P value < .05 was considered significant. All analysis was undertaken using MATLAB (R2013b, Mathworks, Inc, Natick, MA, USA). Figure 1 shows the median and quartiles of the responses to the clinical protocol. Table 3 compares measured G 0 and calculated G TARGET across participants and weeks of testing, as well as the SI values from the SFA and VGT models (SI SFA and SI VGT , respectively). There were significant differences between the pooled patient specific and week specific G 0 and calculated G TARGET values in this cohort (Signed rank sum: P rs < .0001, Kolmogorov-Smirnov: P ks < .0001). In particular, there were significant differences across the two modeling approaches in calculated SI values (P rs < .0001, P ks < .0001). Figure 2 shows the individual relationships between G 0 used in the SFA model and calculated G TARGET from the VGT model for all participants and weeks. Note the bias about the 1:1 line indicating that, in almost all cases, the calculated G TARGET < G 0 for this cohort. There were only 4 exceptions over 36 results (11.1%). Figure 3 exhibits a general reduction in SI VGT values compared to SI SFA . for the SI SFA . Figure 4 shows the distribution of measured G 0 and calculated G TARGET across SI values from the two models. (Table 3) . Over all participants and trials, the fit-to-data is better for the VGT model (median absolute residual error (RE) = 0.080 mmol·L -1 vs RE = 0.523 mmol·L -1 for the SFA model P rs < .0001, P ks < .0001).
Results

Discussion
Typical model-based SI measurement strategies set G TARGET equal to G 0. [12] [13] [14] [15] [16] [17] [18] [19] 23 However, for some individuals with type 2 diabetes, this strategy ultimately leads to poor model-to-data fits, SI values that are unlikely to represent the participant's underlying metabolic status ( Figure 5) . 20 While there is no evidence to support the necessity of calculating G TARGET in healthy cohorts ( Figure 5A) , 28, 29 Figure 5B shows how the inclusion of G TARGET as a model variable was necessary to achieve a good model fit to data. The inclusion of G TARGET as a model variable also shifted the SI to a more expected value for this patient. While the improved residual was expected due to additional variable in the VGT model, the six-fold improvement in residual error (0.080 mmol·L -1 vs RE = 0.523 mmol·L -1 ) implies calculating G TARGET was necessary for this cohort with type 2 diabetes.
However, when G 0 ≈ G TARGET , the fitted glucose profiles from both models matched measured plasma glucose data well ( Figure 5 ). The residual errors in Figure 5A were 0.166 mmol·L -1 compared to 0.135 mmol·L -1 for the SFA and VGT models, respectively. This result implies that, when the G 0 ≈ G TARGET the adapted model provides minimal benefit and no impediment and thus, the SI values across the approaches were effectively equivalent. However it is important to note that it is not possible to know when this equality assumption is correct a priori. ). This agreement with prior research implies that the inclusion of G TARGET enables a more accurate measure of insulin sensitivity. Table 3 shows while most participants had elevated fasting (G 0 ) glucose levels, G TARGET was calculated closer to a normal reference range of 4.0 to 5.6 mmol·L -1 . 30 In particular, 14 of the 36 calculated G TARGET values (38.9%) were in the normal, healthy range, while only 2 of 36 G 0 values (5.6%) were in that range. Figure 2 shows that G 0 was typically higher than calculated G TARGET , with only 4 exceptions over 36 results (11.1%). These results imply that most individuals with type 2 diabetes have a lower set point G TARGET level than assumed by G 0 and would thus perhaps attain lower glucose levels if exogenous insulin and/or longer-term fasting was introduced. 31 Participant 8 was diagnosed with diabetes 7 years prior to the study. While their SI remained in the healthy range for the duration of the intervention (Table 3) , they also had elevated G 0 for the duration of the intervention. However, when increased levels of insulin were introduced by the IM-IVGTT, the participant's glycemic response tended toward a value much lower than the fasting value of G 0 and toward the approximately 4.0 mmol·L -1 (Table 3) . Furthermore, the SI SFA would be more expected from a very fit, healthy individual. 12 In contrast, the SI VGT was more inline with expected behavior for individuals with long-term type 2 diabetes. 1, 12 Participant 10 experienced a modest weight loss between week 0 and week 12 (0.8%) and a concurrent improved in SI value (Table 3) . However, during the second study period, the participant failed to comply with the diet and gained 4.2% body weight. Hence, the SI of Participant 10 fell between week 12 and week 24. This result aligns with the general trend of improved SI due to weight loss.
3,32 Participant 10 had consistent G TARGET values within the healthy range across each trial despite changes in diet that manifested in weight gain and SI loss. In contrast, their G 0 values at week 0 and 12 were slightly elevated, and the week 24 G 0 was a highly elevated 9.92 mmol·L -1 . This result shows while the change in diet had a quick effect on G 0 , G TARGET remained consistently at a healthy level throughout the intervention. Hence, the adapted VGT modeling approach captured a stable, underlying and important aspect of this participant's metabolic state, despite noticeable apparent changes in their physiology.
Participant 11 achieved numerous physiological improvements as a result of the intervention. In particular, their BMI dropped, and G 0 improved. However, the SI SFA values do not exhibit the expected improvement in insulin sensitivity for this participant. In contrast, when G TARGET was calculated, the SI VGT values of this participant were consistently and noticeably improved in concert with weight loss. Thus, calculating G TARGET as was critical to capturing the expected changes in SI for Participant 11. In contrast, the G TARGET = G 0 assumption effectively obscured this result.
Participant numbers are a possible limitation with only 12 subjects and 36 tests. In particular, greater participant variability is typically used to justify model proposals like that presented here. However, in this case, the proposed variance to the model is primarily intended for individuals with established diabetes. Thus, the optimal cohort should span of dysfunction within expected within type 2 diabetes, which is well captured in this cohort. This cohort has individuals with 1 to 11 years since diagnosed, and thus was suitable for establishing model fit and individual behaviors.
Nine of the 12 participants had glycemic responses tending toward a healthy G TARGET value (4 to 5.6 mmol·L -1 ). However, all participants had impaired fasting glucose at week 0. Two of the three individuals (Participants 1, 3, 7) with elevated G TARGET values had confirmed long-term diabetes (Table 1 ). These latter results may imply that irregular glycemic targets could be a late onset dysfunction of the disease. However, greater participant numbers are required to confirm this outcome. This potential mechanism of dysfunction in established type 2 diabetes is not currently recognized by diabetologists or physiological modelers. However, this research has shown G TARGET was variable, identifiable, and had a large effect on a model-based analysis of dynamic glycemic data. The results justify prospective studies to determine whether G TARGET is significantly higher in individuals with longer term established type 2 diabetes, and whether the variable can augment and improve the stability of other glycemic models. 
Conclusions
G TARGET should be considered as a variable when modeling the glycemic metabolism of individuals with type 2 diabetes. In particular, incorporating G TARGET as a calculated variable in dynamic SI tests in type 2 diabetes may modulate SI toward more physiologically representative values that could strengthen the findings of many retrospective clinical trials.
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